1. Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, et al. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: a prospective multicentre study. Jt Bone Spine. 2017;84(2):169–73.
2. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19(17):2591–602.
3. Tauscher AE, Fleischer AB, Phelps KC, Feldman SR. Psoriasis and pregnancy. JCMS. 2002;6(6):561–70.
4. EuropeanMedicinesAgency. Summary of Product Characteristics (SmPC) Etanercept (Enbrel) European Medicines Agency 2019; https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf. Assessed July 2019.
5. EuropeanMedicinesAgency. Summary of Product Characteristics (SmPC) Infliximab (Remicade) European Medicines Agency 2019; https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf. Assessed July 2019.